Under the terms of the agreement, Iverson Genetics will use ParagonDx’s products to test patients to determine if they possess genetic traits shown to increase or decrease sensitivity to warfarin.
Dean Sproles, CEO and founder, Iverson Genetics, said: “Doctors need to make dosing decisions about warfarin on the spot. Our same-day turnaround will bring the benefits of genetic testing to patients immediately. Doctors and clinics have enthusiastically welcomed our warfarin test, and we expect to do at least 5,000 tests per month by July, 2008.”